Cargando…
Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531232/ https://www.ncbi.nlm.nih.gov/pubmed/33072689 http://dx.doi.org/10.3389/fpubh.2020.00517 |
| _version_ | 1783589723034353664 |
|---|---|
| author | Grischott, Thomas |
| author_facet | Grischott, Thomas |
| author_sort | Grischott, Thomas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7531232 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75312322020-10-17 Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018 Grischott, Thomas Front Public Health Public Health Frontiers Media S.A. 2020-09-09 /pmc/articles/PMC7531232/ /pubmed/33072689 http://dx.doi.org/10.3389/fpubh.2020.00517 Text en Copyright © 2020 Grischott. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Public Health Grischott, Thomas Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018 |
| title | Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018 |
| title_full | Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018 |
| title_fullStr | Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018 |
| title_full_unstemmed | Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018 |
| title_short | Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018 |
| title_sort | commentary: accessibility of cancer drugs in switzerland: time from approval to pricing decision between 2009 and 2018 |
| topic | Public Health |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531232/ https://www.ncbi.nlm.nih.gov/pubmed/33072689 http://dx.doi.org/10.3389/fpubh.2020.00517 |
| work_keys_str_mv | AT grischottthomas commentaryaccessibilityofcancerdrugsinswitzerlandtimefromapprovaltopricingdecisionbetween2009and2018 |